<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079425</url>
  </required_header>
  <id_info>
    <org_study_id>NXC736-001</org_study_id>
    <nct_id>NCT05079425</nct_id>
  </id_info>
  <brief_title>A First-in-Human Study to Assess Single and Multiple Doses of NXC736 in Healthy Participants</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect After the Oral Administration of NXC736 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NEXTGEN Bioscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NEXTGEN Bioscience</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo- controlled, single and multiple dosing,&#xD;
      dose-escalation clinical phase 1 trial to investigate the safety, tolerability,&#xD;
      pharmacokinetics and pharmacodynamics of NXC736 after oral administration in healthy male&#xD;
      volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Day 49</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 49</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Vital Sign Abnormalities</measure>
    <time_frame>Day 49</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>Day 49</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Clinical Laboratory Abnormalities</measure>
    <time_frame>Day 49</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A: Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose (SAD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose (SAD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Ascending Dose (MAD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NXC736</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Part A: Fasting</arm_group_label>
    <arm_group_label>Part A: Fed</arm_group_label>
    <arm_group_label>Part B: Fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Part A: Fasting</arm_group_label>
    <arm_group_label>Part A: Fed</arm_group_label>
    <arm_group_label>Part B: Fasting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult males aged between 19 and 55 at screening&#xD;
&#xD;
          -  Those whose weight is between 55 and 90 kg and BMI is between 18.0 and 30.0&#xD;
&#xD;
          -  Those who are adequate to be subjects in this study upon judgment of the investigator&#xD;
             after physical examination, clinical laboratory test, examination by interview, etc&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who have clinical significant liver, kidney, nervous system, respiratory,&#xD;
             endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or&#xD;
             past history&#xD;
&#xD;
          -  Those who have gastrointestinal diseases or past history of gastrointestinal diseases&#xD;
             that may affect safety and pharmacokinetic/pharmacodynamic evaluation of study drug,&#xD;
             and those who have past history of gastrointestinal surgery (however, except simple&#xD;
             appendectomy and herniotomy)&#xD;
&#xD;
          -  A person who shows any of the following results in vital signs at the time of&#xD;
             screening&#xD;
&#xD;
               -  Systolic blood pressure below 90 mmHg or above 140 mmHg&#xD;
&#xD;
               -  diastolic blood pressure less than 50 mmHg or greater than 90 mmHg&#xD;
&#xD;
               -  Pulse rate less than 50 beats per minute or more than 90 beats per minute&#xD;
&#xD;
          -  A person who exhibits any of the following results from a 12-lead ECG test at the time&#xD;
             of screening:&#xD;
&#xD;
               -  PR &gt; 210 msec&#xD;
&#xD;
               -  QRS complex &gt; 120 msec&#xD;
&#xD;
               -  QTcB &gt; 450 msec&#xD;
&#xD;
          -  A person who exhibits any of the following results in a clinical laboratory&#xD;
             examination at the time of screening ;&#xD;
&#xD;
               -  glomerular filtration rate (eGFR, CKD-EPI) &lt; 60 mL/min/1.73 m2&#xD;
&#xD;
               -  WBC count &lt; 3500/μL&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 1500/μL&#xD;
&#xD;
               -  AST/ALT &gt; 1.5 X ULN&#xD;
&#xD;
          -  Those who have a history of tuberculosis infection or who have confirmed positive&#xD;
             tuberculosis infection as a result of the Quantiferon TB-Gold test and Chest X-ray&#xD;
             performed at the screening test&#xD;
&#xD;
          -  Persons with acute infectious diseases including herpes virus infection, herpes&#xD;
             simplex, and herpes zoster&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seungwhan Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University College of Medicine and Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seungwhan Lee, Ph.D.</last_name>
      <phone>82-2-2072-0255</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

